Roivant Sciences Ltd.(ROIV)Earnings, Financials & Key RatiosRoivant Sciences Ltd. (ROIV) stock price & volume — 10-year historical chart
Investment Thesis • Updated 2025Q4
while the $1.4 billion cash buffer provides significant downside protection, the persistent negative FCF margin of -65.5% and reliance on non-operating income suggest that the current valuation of 2966.77x P/S may be disconnected from core operational performance.
Roivant Sciences Ltd. (ROIV) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Roivant Sciences Ltd. (ROIV) EPS & revenue vs analyst estimates — last 4 quarters
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 20, 2026 | $0.28vs $0.29+3.5% | $3Mvs $3M-26.2% |
| Q1 2026 | Feb 6, 2026 | $0.24vs $0.30+19.9% | $2Mvs $5M-60.6% |
| Q4 2025 | Nov 10, 2025 | $0.20vs $0.32+36.9% | $2Mvs $6M-72.0% |
| Q3 2025 | Aug 11, 2025 | $0.18vs $0.25+27.9% | $2Mvs $7M-70.3% |
Recent stock market news and headlines for Roivant Sciences Ltd. (ROIV)
Roivant Sciences anticipates three commercial launches over the next few years, led by brepocitinib. The stock is arguably expensive now, even with aggressive revenue estimates for 2031.
Key metrics vs top competitors for Roivant Sciences Ltd. (ROIV)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $36.31 | $26.12B | -84.44 | -71.57% | -3629.19% | -5.72% | — | |
| $15.55 | $1.65B | -2.27 | — | — | -866.46% | — | |
| $40.09 | $8.23B | -14.47 | — | — | -68.16% | — | |
| $119.24 | $9.74B | -32.31 | -16.72% | -612.17% | -25.02% | — | |
| $323.95 | $9.36B | -24.03 | -100% | — | -43.02% | — | |
| $254.65 | $449.91B | 107.45 | 8.57% | 5.79% | 67.46% | — |
Roivant Sciences Ltd. (ROIV) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Roivant Sciences Ltd. (ROIV) SEC filings — annual & quarterly reports (10-K, 10-Q)
May 20, 2026·SEC
Apr 2, 2026·SEC
Mar 3, 2026·SEC
Get notified when ROIV posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Roivant Sciences Ltd. (ROIV) stock FAQ — growth, dividends, profitability & financials explained
Roivant Sciences Ltd. (ROIV) reported $8.3M in revenue for fiscal year 2025. This represents a 88% decrease from $67.7M in 2019.
Roivant Sciences Ltd. (ROIV) saw revenue decline by 71.6% over the past year.
Roivant Sciences Ltd. (ROIV) reported a net loss of $299.8M for fiscal year 2025.
Roivant Sciences Ltd. (ROIV) has a return on equity (ROE) of -5.7%. Negative ROE indicates the company is unprofitable.
Roivant Sciences Ltd. (ROIV) had negative free cash flow of $758.6M in fiscal year 2025, likely due to heavy capital investments.
